1Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, India.
2Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, India
*Corresponding Author: Vasudev Pai, Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, India. Email: pai.vasudev@manipal.edu. Tel: 09964436409
Online published on 3 February, 2014.
Breast cancer is the most common forms of female cancers. External factors like obesity, late pregnancies or no pregnancies, use of tobacco and alcohol have increased the risk of cancer in women. Targeted therapy is new type of cancer treatment that uses drugs precisely and attaches cancer cells with minimum damage to normal cells. It is multimodality cancer treatment regimens that include chemotherapy, surgery and radiation therapy. It has limited toxicity and target cancer cells which carry specific receptors (estrogen receptor). Third generation Aromatase Inhibitors (AIs) like Exemestane are emerging as potential therapeutic agents for breast cancer.
Radiation therapy, Monoclonal antibody, Selective estrogen receptor modulators (SERM), Estrogen receptor down regulator (ERD), Aromatase Inhibitors(AIs)